BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 1, 2009

View Archived Issues

SJL-01 exhibits safety and potent anti-leishmania activity in preclinical evaluation

Read More

Rohto claims novel collagen production-promoting peptides for RA

Read More

Novel nAChR modulators in early development at NeuroSearch

Read More

Amira Pharmaceuticals describes CRTH2 antagonists for respiratory disorders

Read More

Novel compounds for the treatment of glaucoma claimed by Allergan

Read More

FDA clears Agriflu seasonal influenza vaccine

Read More

Lorus Therapeutics reports results of phase II LOR-2040 trial in AML

Read More

Spectrum completes enrollment in phase III trial of apaziquone in bladder cancer

Read More

Novel 2,3-dioxygenase inhibitor disclosed by Incyte for cancer immunotherapy

Read More

3,4-DAP obtains FDA orphan drug status for Lambert-Eaton myasthenic syndrome

Read More

S*BIO presents its novel, potent dual PI3K/mTOR inhibitor SB-2312

Read More

Proacta reports data on its novel hypoxia-activated pan-HER inhibitor

Read More

EMEA grants Clinuvel the status of small and medium enterprise

Read More

Chronic sildenafil improves clinical outcomes in heart failure patients

Read More

Lp-PLA2 levels did not predict CVD risk in atorvastatin-treated diabetic subjects

Read More

Bavarian Nordic to file for market approval for Imvamune smallpox vaccine in Canada

Read More

Novartis claims Toll-like receptor agonists for the treatment of asthma

Read More

CB1 receptor antagonists described by sanofi-aventis for the treatment of obesity

Read More

EMD Serono receives refuse to file letter from FDA on cladribine NDA

Read More

Cytokine completes phase I trial of CPSI-2364

Read More

Novavax completes enrollment in phase IIa seasonal influenza vaccine study

Read More

Angiox approved in E.U. for additional indication

Read More

FDA approves Cymbalta for maintenance treatment of GAD

Read More

Lundbeck initiates clinical phase II Lu-AE-58054 trials in Alzheimer's disease

Read More

Stemline Therapeutics expands oncology program directed at cancer stem cells

Read More

PPD completes acquisition of BioDuro

Read More

Tripep completes phase I trial of ChronVac-C hepatitis C virus DNA vaccine

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing